BioSpace News Archive

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET ( 1:30 p.m. PT ).

IACTA Pharmaceuticals, Inc. today announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800

Inscopix, Inc. today announced it appointed David Gray, Ph.D., as Chief Scientific Officer (CSO)

Beroni Group, an Australia-based biopharmaceutical enterprise, announced that its article entitled “Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies” has been accepted for publication and undergone full review in the FEBS Journal.

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors.

GenesisCare — one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom — today announced it will be expanding access to the novel fluorinated prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging capabilities in its Florida, South Carolina, and Texas centers.

Aldeyra Therapeutics, Inc. today reported recent corporate highlights and financial results for the quarter ended September 30, 2021.

There’s a new drug in development that could prevent the next global pandemic. Researchers at Texas A&M University Health Science Center ( Texas A&M Health ) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.

Abiomed, Inc. today announced financial results for the quarter ended September 30, 2021.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that its patent titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation” has been granted in Hong Kong and Mexico, and has received a notice of allowance in Japan.